When should antiplatelet therapy be initiated in a patient with ischemic heart disease who has had an intracerebral hemorrhage?

When to Start Antiplatelets After Intracerebral Hemorrhage in IHD Patients

For patients with ischemic heart disease who have suffered intracerebral hemorrhage, antiplatelet monotherapy should be resumed at 7–10 days after ICH onset if repeat imaging confirms hemorrhage stability and blood pressure is controlled below 130/80 mmHg. 1, 2

Immediate Management

• Stop all antiplatelet agents immediately upon ICH diagnosis and reverse any coagulopathy. 1
• Obtain urgent neurosurgical consultation to evaluate hematoma stability and need for intervention. 1
• Do not restart antiplatelets until brain imaging confirms no hematoma expansion. 2

Risk Stratification Framework

Very High Thromboembolic Risk (Restart at 7–10 Days)

Patients in this category warrant earlier resumption at 7–10 days after confirming hemorrhage stability:

• Recent coronary stenting within 1–3 months (especially drug-eluting stents requiring continued P2Y12 inhibition). 1
• Mechanical heart valves (thromboembolic risk >7% per year). 1
• CHADS₂ score ≥4 (thromboembolic risk >7% per year). 1
• History of multiple prior ischemic strokes. 1, 2

Moderate Thromboembolic Risk (Restart at 7–10 Days)

• Stable coronary artery disease with prior myocardial infarction. 1, 2
• CHADS₂ score 2–3. 2
• Prior ischemic stroke (single event). 2

Lower Risk (Consider Delayed Restart at 4–6 Weeks)

• Stable IHD without recent events and no high-risk features. 2
• Uncertainty about hemorrhage stability. 2

Hemorrhage Location Matters

The location of ICH significantly impacts recurrence risk and should guide timing:

• Deep hemorrhages (basal ganglia, thalamus) have lower recurrence risk and favor earlier restart at 7–10 days. 1, 2
• Lobar hemorrhages suggest possible cerebral amyloid angiopathy with very high rebleeding risk; delay restart to 4–6 weeks or avoid entirely. 1, 2
• Multiple microbleeds on MRI (≥5) increase ICH recurrence risk approximately 9-fold versus 1% without microbleeds; strongly consider delaying or avoiding restart. 2

Mandatory Pre-Restart Requirements

Before resuming any antiplatelet therapy, ensure:

• Repeat CT or MRI shows no hematoma expansion (typically performed at 24–48 hours and again before restart). 2
• Blood pressure controlled to <130/80 mmHg (uncontrolled hypertension increases recurrent ICH risk 4.3-fold). 2
• Neurological examination is stable without deterioration. 2

Medication Selection

• Aspirin 75–100 mg daily is the preferred first-line agent. 2, 3
• Clopidogrel 75 mg daily is an acceptable alternative with modestly lower gastrointestinal bleeding risk. 2
• Dual antiplatelet therapy (aspirin + clopidogrel) must be avoided after any ICH due to markedly increased bleeding risk. 1, 2, 3

Special Situation: Recent Coronary Stenting

For patients with coronary stents placed within 1–3 months before ICH:

• Continue P2Y12 inhibitor monotherapy (clopidogrel 75 mg preferred) starting at 7–10 days. 1
• Stop aspirin if dual therapy was being used. 1
• Discontinue all antiplatelets after standard DAPT duration ends (typically 1–3 months post-stenting). 1
• Consult interventional cardiology to determine minimum acceptable antiplatelet duration based on stent type and thrombosis risk. 1

Evidence Quality

The RESTART trial (2019) provides the highest-quality randomized evidence, showing that antiplatelet resumption did not increase recurrent ICH risk (adjusted HR 0.51,95% CI 0.25–1.03, p=0.060) and may even reduce it. 4, 1 This trial reassures that starting antiplatelet therapy is unlikely to increase recurrent ICH compared with avoidance over 2 years. 4

A 2025 meta-analysis of 5,554 patients demonstrated that early antiplatelet therapy significantly reduced recurrent ICH by 46% (RR 0.54,95% CI 0.37–0.78, p=0.001) without increasing ischemic complications. 5

Current American Heart Association/American Stroke Association guidelines (2023) classify antiplatelet resumption after ICH as Class IIa, Level B-R evidence, stating it is "reasonable" for secondary thromboembolic prevention. 1, 2

Critical Pitfalls to Avoid

• Never restart without repeat imaging confirming hemorrhage stability. 2
• Never restart with uncontrolled blood pressure (>130/80 mmHg). 2
• Never use dual antiplatelet therapy after ICH—bleeding risk far exceeds any benefit. 1, 2
• Do not automatically restart at 24–48 hours for most patients; this timing is only appropriate for very small, punctate hemorrhages with compelling indications like recent stenting. 2
• Consider hemorrhage location carefully—lobar ICH in elderly patients suggests amyloid angiopathy with very high rebleeding risk. 1, 2

Hemorrhagic Transformation Exception

If the patient had asymptomatic hemorrhagic transformation of an ischemic stroke (not primary ICH), continuation of antiplatelet monotherapy may be reasonable after confirming radiologic stability at approximately 7–10 days, as hemorrhagic transformation has a different natural history than primary ICH. 1